Collin Hovinga serves as VP of Rare and Orphan Disease Programs at C-Path, where he leads major initiatives including the Rare Disease Cures Accelerator and the Critical Path for Rare Neurodegenerative Diseases. With a PharmD from Creighton University and a Master of Epidemiology, his background includes specialized fellowships in pediatric neuroscience and clinical pharmacology at the FDA. Dr. Hovinga is an international expert in pediatric and rare disease research, focusing on optimizing medication safety and efficacy for underserved patient populations.
